News >

Best Practices With CAR T-Cell Therapy Being Refined in Lymphomas

Sarah Karlovitch and Gina Columbus
Published: Wednesday, Jul 03, 2019

Alison R. Sehgal, MD

Alison R. Sehgal, MD

The addition of CAR T-cell therapy to the lymphoma armamentarium continues to lead to encouraging outcomes for relapsed/refractory patients. However, a host of other strategies have come to the forefront, including adverse event (AE) management, potential widespread administration, and further CAR T-cell products emerging in the pipeline.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Practice Connections™: From Diagnosis to Emerging Immunotherapeutic Options: Understanding the Burden and Risks in Peanut AllergySep 28, 20191.0
Enduring CME activity from the School of Breast Oncology®: 2018 Mid-Year Video UpdateSep 28, 20192.0
Publication Bottom Border
Border Publication
x